{"prompt": "['PROTOCOL SYNOPSIS', 'Unique Identifier', 'HO-16-17264', 'Abbreviated Title', 'Qualitative research to categorize nasal polyps', 'GSK Product', 'Mepolizumab', 'Rationale', 'GlaxoSmithKline (GSK) is embarking on a clinical program to', 'assess treatment of severe, recurrent nasal polyps with an anti-', 'interleukin-5 (anti-IL5) (mepolizumab). Patient symptomatic', 'endpoints will form the basis for the assessment of treatment', 'benefit of nasal polyp therapies. Currently, there is a lack of', 'published qualitative data regarding nasal polyps to understand', 'the symptoms (specific symptoms, duration, frequency,', 'severity) or health-related quality of life (HRQoL) impacts for', 'patients, as well as the patient decision-making process in', 'electing for surgery and their pre- and post-surgical experience', 'to treat nasal polyps. In line with regulatory requirements, the', '1,2', 'patient experience of nasal polyps will need to be characterized.', 'Additionally, there is a requirement to evaluate existing', 'symptomatic endpoints with respect to relevance and', \"comprehensiveness within this population to inform GSK's\", 'clinical outcome assessment (COA) strategy for this trial.', 'To address this unmet need GSK would like to conduct a', 'qualitative research study with adult patients with nasal polyps', 'to explore the disease experience from the patient perspective', 'and to debrief existing symptomatic PROs (including overall and', \"single item VAS's and the SNOT-22), via patient interviews and\", 'real-time data capture. This protocol details the methods and', 'procedures that will be used in the conduct of this study.', 'Objectives', 'Primary', '(Primary, Secondary)', 'To explore the symptom, impact and surgery experience of', 'patients with severe, recurrent nasal polyps and obtain patient', 'feedback regarding the adequacy of the SNOT-22 and GSK', 'VAS assessments (in terms of relevance and', 'comprehensiveness) in assessing disease experience in nasal', 'polyps.', 'Secondary', 'Combined concept elicitation (CE) and cognitive debriefing', '(CD) interviews', 'Concept elicitation objectives:', 'GK7818Av7_0', 'Page 4 of 131', 'Effective: 20 Jan 2017']['To identify through open-ended questioning the concepts that', 'are important to patients with severe, recurrent, nasal polyps,', 'who have been treated with surgery and the language they use', 'to describe their disease experience. The main areas of', 'exploration will be the symptoms with particular attention paid to', 'the frequency, severity, duration and bother of each symptom,', \"patients' surgical decision-making and surgical/treatment\", 'experience and the functional and HRQol impact experienced', 'by patients.', 'Cognitive debriefing objectives:', 'To cognitively test and explore the content and face validity of', 'existing PRO instruments (single item VAS and SNOT-22) via', 'assessment of the relevance and appropriateness of the items', \"included in the instruments and the participants' ability to read,\", 'and consistently understand the instrument item wording,', 'instructions, response option and recall period.', 'Real-time data capture app', 'To explore the patient experience of the symptoms, HRQoL', 'impacts and treatment of nasal polyps and any day-to-day', \"variability that exists in these experiences in 'real time' using\", 'smartphone/tablet app based technology.', 'Study Design', 'This is a cross-sectional qualitative study comprising the', 'conduct of semi-structured combined CE and CD telephone', 'interviews (each 120 minutes in duration) with US (n=20) and', 'German (n=10) adults with severe, recurrent nasal polyps. The', 'combined CE and CD interviews aim to investigate the patient', 'experience of nasal polyps, and the relevance and', 'understanding of existing PRO instruments (e.g. VAS and', 'SNOT-22). In addition to the interview, the study includes a real-', 'time data capture task conducted with 10 of the 20 US', 'participants over a 10-day period using smartphone/tablet app-', 'based technology. Five of the ten participants (50%) will take', 'part in the app task prior to their interview and the remaining', 'five participants (50%) will take part in the app task following', 'their interview.', 'This study will be conducted by Adelphi Values, an independent', 'research agency specializing in health outcomes research, on', 'behalf of GSK.', 'Study Population and', 'A sample of 20 US-English speaking patients and 10 German', 'Sampling Methods', 'patients will be recruited, giving a collective sample of 30', 'patients. Recruitment will be facilitated by third-party vendors in', 'GK7818Av7_0', 'Page 5 of 131', 'Effective: 20 Jan 2017']\n\n###\n\n", "completion": "END"}